Atea Pharmaceuticals Inc (AVIR) 13F Filing Data & Analysis (Q2 2026)

AVIR ranks #4061 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

AVIR is a top-conviction position for BML Capital Management, LLC — at 18.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in AVIR belongs to FMR LLC, but the position matters far more to BML Capital Management, LLC, who has 18.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Acadian Asset Management LLC has added to its AVIR position for two straight quarters, increasing it by $4.8M to reach $9.5M today.

Israel Englander has trimmed its AVIR position for two straight quarters, cutting it by $1.1M while still holding $1.4M.

AVIR is up 3.8% today, and institutions have been net buyers of $9.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AVIR reported a net loss of $165.3M over the trailing twelve months.

• Not yet profitable — net loss of $165.3M over the trailing twelve months
• Net income declined year over year, from -$136.1M to -$165.3M
• Operating cash flow was negative, using $132.0M in cash
• Current ratio of 7.82x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range